Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Publication date: July 2020Source: The Lancet Haematology, Volume 7, Issue 7Author(s): Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Goy, Joost S P Vermaat, Olivier Casasnovas, Nada Hamad, Josée M Zijlstra, Sameer Bakhshi, Reda Bouabdallah, Sylvain Choquet, Ronit Gurion, Brian Hill, Ulrich Jaeger, Juan Manuel Sancho, Michael Schuster, Catherine Thieblemont, Fátima De la Cruz, Miklos Egyed
Source: The Lancet Haematology - Category: Hematology Source Type: research
More News: Hematology | Lymphoma